FOLH1 and prostate cancer: The Enzap trial enrolled patients with metastatic castration-resistant prostate cancer who had not previously received docetaxel or androgen receptor pathway inhibitors and displayed PSMA-positive PET/CT scans with [68Ga]Ga-PSMA-11.